Table III.
Estimation of blood management costs and cost savings in patients undergoing total hip or knee arthroplasty, managed with 600 mg intravenous iron sucrose (IS) or ferric carboxymaltose (FCM), compared to those from the control group.
| N. | Cost scenarios | |||
|---|---|---|---|---|
|
|
||||
| ALO-1 | ALO-2 | ALO-3 | ||
| Blood management costs | ||||
| Control | ||||
| Without ARCT (€/patient) | 134 | 0 | 0 | 0 |
| With ARCT(€/patient) | 48 | 521 | 841 | 1,161 |
| Mean cost (€/patient) | 182 | 137.5 | 221.9 | 306.3 |
| Range | 0–972 | 0–1,292 | 0–1,612 | |
|
| ||||
| IS (600 mg) | ||||
| Without ARCT (€/patient) | 117 | 105 | 105 | 105 |
| With ARCT (€/patient) | 17 | 562 | 882 | 1,202 |
| Mean cost (€/patient) | 134 | 163.0 | 203.6 | 244.2 |
| Range | 105–834 | 105–1,154 | 105–1,474 | |
|
| ||||
| FCM (600 mg) | ||||
| Without ARCT (€/patient) | 44 | 138 | 138 | 138 |
| With ARCT (€/patient) | 4 | 745 | 1,065 | 1,385 |
| Mean cost (€/patient) | 48 | 188.6 | 215.3 | 241.9 |
| Range | 138–1,110 | 138–1,430 | 138–1,750 | |
|
| ||||
| Cost differences | ||||
| IS vs control | ||||
| Mean (€/patient) | −25.5 | +18.3 | +62.1 | |
| 95% CI | (−73.8–22.8) | (−57.4–93.9) | (−41.7–165.9) | |
| p | 0.299 | 0.635 | 0.240 | |
|
| ||||
| FCM vs control | ||||
| Mean (€/patient) | −51.1 | +6.6 | +64.4 | |
| 95% CI | (−126.8–24.6) | (−109.4–122.6) | (−92.9–221.7) | |
| p | 0.185 | 0.910 | 0.421 | |
|
| ||||
| FCM vs IS | ||||
| Mean (€/patient) | −25.6 | −11.7 | +2.2 | |
| 95% CI | (−80.1–28.9) | (−99.2–75.9) | (−118.9–123.4) | |
| p | 0.356 | 0.793 | 0.971 | |
Data calculations take into account both allogeneic blood and intravenous iron management costs (ALO-1), plus a hospital stay prolonged by 1 day (ALO-2) or 2 days (ALO-3) in patients receiving allogeneic red cell transfusion (ARCT). Cost differences: control costs – IV iron costs, expressed as mean and 95% confidence interval (CI); (+) cost savings, (−) incremental cost.